Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Revive Therapeutics Announces Proposed Private Placement

Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.

By The Northwire Desk — AI Analysis Jun 26, 2026 · 16:15 RVV · 0.03 Revive Therapeutics Ltd.
Executive Summary
  • Revive Therapeutics announced a proposed private placement of up to 31,250,000 units at $0.032 per unit.
  • Gross proceeds are targeted at approximately $1,000,000.
  • Each unit comprises one common share and one common share purchase warrant exercisable at $0.05 per share for 36 months.
  • Proceeds will be used for working capital.
  • The transaction may close in tranches, subject to customary conditions, with a 4-month and 1-day hold period for investors.
  • Finder compensation is set at 8.0% cash plus 8.0% in warrants with identical terms.
Material Impact
  • The company is in a severe liquidity crisis, with a going concern warning, negative equity of -$4.0M, and only ~$12,665 to $22,665 in cash.
  • The $1M raise is strictly a survival mechanism. It covers a fraction of the $4.15M working capital deficiency and provides roughly 6 months of runway based on a ~$0.17M monthly burn rate.
  • Dilution is immediate and significant: ~7.2% from the share issuance, plus additional dilution from the warrants and finder warrants.
  • The placement price of $0.032 is at a slight premium to the recent $0.03 trading range, but the out-of-the-money warrants ($0.05) limit immediate upside dilution pressure.
  • This does not alter the fundamental risk profile; it merely extends the timeline to the next inevitable capital raise.
RVV · Price
Company Overview
  • Revive Therapeutics is a clinical-stage biotechnology company focused on drug repurposing and medical countermeasures.
  • Core asset: Bucillamine, a thiol-based drug with over 30 years of clinical history in Japan and South Korea for rheumatoid arthritis.
  • Strategic pivot: Expanding bucillamine into infectious diseases, nerve-agent exposure, chemical threats, and long COVID.
  • Secondary pipeline: Psilocybin therapeutics, currently paused pending financing.
  • Business model: Relies on intellectual property expansion, government partnerships (e.g., DRDC), and potential licensing or procurement contracts rather than direct commercial sales.
Read the original news release →

More from Revive Therapeutics Ltd.

May 20, 2026 · 07:45

Revive Therapeutics Patents Fuel Defense Strategy Amidst Price Consolidation

M&A / Property Mar 11, 2026 · 17:34

Revive Therapeutics advances bucillamine patents

M&A / Property Mar 11, 2026 · 07:30

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

M&A / Property Dec 15, 2025 · 17:09

Revive Therapeutics primes the pump on Bucillamine

Other Dec 15, 2025 · 07:30

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Other Nov 21, 2025 · 16:56

Revive talks DRDC study on bucillamine for nerve agents

Other